Lexeo Therapeutics (LXEO) Operating Income (2022 - 2026)
Lexeo Therapeutics recorded quarterly Operating Income of -$22.3 million in Q1 2026, up 3.39% quarter-over-quarter from -$23.1 million in Q4 2025, and up 33.94% year-over-year from -$16.7 million in Q1 2025.
Lexeo Therapeutics' Operating Income history runs 5 years deep, the most recent figure standing at -$22.3 million for Q1 2026.
- In Q1 2026, Operating Income rose 33.94% year-over-year to -$22.3 million; the TTM figure through Mar 2026 stood at -$97.8 million (down 213.56% YoY), while the FY2025 annual figure was -$109.3 million, down 428.55% from the prior year.
- Operating Income came in at -$22.3 million for Q1 2026 at Lexeo Therapeutics, up from -$23.1 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $57.7 million in Q4 2024 to a low of -$33.8 million in Q1 2025.
- A 5-year average of -$16.9 million and a median of -$21.6 million in 2025 frame the typical range for Operating Income.
- Across the five-year window, Operating Income soared 485.42% in 2024 and plunged 140.05% in 2025, its largest moves.
- Lexeo Therapeutics' Operating Income stood at -$15.2 million in 2022, then advanced by 1.47% to -$15.0 million in 2023, then jumped by 485.42% to $57.7 million in 2024, then slumped by 140.05% to -$23.1 million in 2025, then increased by 3.39% to -$22.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$22.3 million, -$23.1 million, and -$21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -22.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.33 Mn |
| Dec 31, 2025 | -23.12 Mn |
| Sep 30, 2025 | -21.65 Mn |
| Jun 30, 2025 | -30.69 Mn |
| Mar 31, 2025 | -33.81 Mn |
| Dec 31, 2024 | 57.71 Mn |
| Sep 30, 2024 | -31.54 Mn |
| Jun 30, 2024 | -23.55 Mn |
| Mar 31, 2024 | -23.29 Mn |
| Dec 31, 2023 | -14.97 Mn |
| Sep 30, 2023 | -20.27 Mn |
| Jun 30, 2023 | -13.98 Mn |
| Mar 31, 2023 | -19.29 Mn |
| Dec 31, 2022 | -15.20 Mn |
| Sep 30, 2022 | -17.48 Mn |